CEP83

Across TCGA pan-cancer cohorts, CEP83 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CEP83 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CEP83 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CEP83 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

UCEC, SCLC, and THCA are the cancer types where CEP83 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	1.000	0.426	.002	34	view →
SCLC	DFS	Median	II,III,IV	1.000	0.304	.029	7	view →
THCA	DFS	Median	All	0.097	0.841	<.001	6	view →
LGG	DFS	Median	All	0.110	0.833	<.001	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CEP83–UCEC (DFS)

Open the UCEC breakdown →